Vertex Pharmaceuticals Liabilities 2024

Vertex Pharmaceuticals Aktienanalyse

What does Vertex Pharmaceuticals do?

Vertex Pharmaceuticals Inc is a biopharmaceutical company that focuses on researching, developing, and marketing therapies for rare diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts, USA. Since its inception, Vertex has been dedicated to pushing the boundaries of science to develop groundbreaking therapies for diseases such as cystic fibrosis and other rare genetic disorders. The company's history began in 1989 when Joshua Boger, a former employee of Merck & Co., founded the company with the goal of becoming a leading developer of therapies for rare diseases. In 1993, Vertex went public, achieving significant success. In 2012, the company announced the development of the first approved therapy for the treatment of cystic fibrosis, Kalydeco. Since then, Vertex has expanded its technology and production capabilities and continues to work on developing additional therapies for rare genetic disorders. The business model of Vertex Pharmaceuticals Inc is based on researching and developing therapies for rare genetic disorders. The company collaborates closely with patients, leading scientists, and medical professionals to develop groundbreaking therapies. Vertex is a vertically integrated company, handling everything from research and development to production and marketing in-house. This allows the company to maintain control over the entire development and production process to ensure the highest quality products. Vertex is divided into different divisions to organize its activities. The Paris research facility specializes in the development of therapies for cystic fibrosis and other rare genetic disorders. The San Diego facility focuses on the development of treatments for cancer. Additionally, the company maintains research facilities in the UK and Canada. Vertex Pharmaceuticals Inc's most well-known product is Kalydeco, the first approved medication for the treatment of cystic fibrosis targeting a specific genetic mutation. Kalydeco aims to restore the function of a specific protein in the lungs, targeting the underlying cause of the disease. The company has also developed other therapies for cystic fibrosis, including Orkambi and Symdeko, which also target genetic mutations. Vertex also has therapies for cancer in its portfolio, such as the drug VX-970 currently in clinical trials for cancer treatment. In summary, Vertex Pharmaceuticals Inc is a leading biopharmaceutical company focused on developing therapies for rare genetic disorders. Since its founding in 1989, Vertex has continuously improved its technology and production capabilities, becoming one of the most innovative companies in the industry. The company is vertically integrated and consists of various research facilities dedicated to developing therapies for different diseases. Vertex has developed several groundbreaking medications for genetic disorders, including Kalydeco (the first approved medication for cystic fibrosis), Orkambi, and Symdeko. Vertex Pharmaceuticals Inc is an example of how research and development can play a significant role in treating rare diseases. Vertex Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Vertex Pharmaceuticals revenue by segment

34 % Symdeko
32 % Orkambi
24 % Kalydeco
10 % Trikafta

Liabilities Details

Assessing Vertex Pharmaceuticals's Liabilities

Vertex Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Vertex Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Vertex Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Vertex Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Vertex Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Vertex Pharmaceuticals stock

What is the level of liabilities of Vertex Pharmaceuticals this year?

Vertex Pharmaceuticals has a debt balance of 5.15 B USD this year.

What were the liabilities of Vertex Pharmaceuticals compared to the previous year?

The liabilities of Vertex Pharmaceuticals have increased by 21.51% increased compared to the previous year.

What are the consequences of high debt for investors of Vertex Pharmaceuticals?

High liabilities can pose a risk for investors of Vertex Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Vertex Pharmaceuticals?

Low liabilities mean that Vertex Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Vertex Pharmaceuticals affect the company?

An increase in liabilities of Vertex Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Vertex Pharmaceuticals affect the company?

A decrease in the liabilities of Vertex Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Vertex Pharmaceuticals?

Some factors that can influence the liabilities of Vertex Pharmaceuticals include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Vertex Pharmaceuticals so important for investors?

The liabilities of Vertex Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Vertex Pharmaceuticals take to modify the liabilities?

To change its liabilities, Vertex Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Vertex Pharmaceuticals pay?

Over the past 12 months, Vertex Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vertex Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Vertex Pharmaceuticals?

The current dividend yield of Vertex Pharmaceuticals is .

When does Vertex Pharmaceuticals pay dividends?

Vertex Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vertex Pharmaceuticals?

Vertex Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Vertex Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vertex Pharmaceuticals located?

Vertex Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vertex Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vertex Pharmaceuticals from 11/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/26/2024.

When did Vertex Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/26/2024.

What was the dividend of Vertex Pharmaceuticals in the year 2023?

In the year 2023, Vertex Pharmaceuticals distributed 0 USD as dividends.

In which currency does Vertex Pharmaceuticals pay out the dividend?

The dividends of Vertex Pharmaceuticals are distributed in USD.